To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada®) or abacavir/lamivudine (Epzicom®/Kivexa®).
Methods
Three Phase I, open, crossover studies with two (studies 1 and 3) or three (study 2) treatment periods were conducted in healthy individuals. In study 1, individuals received zidovudine and placebo or zidovudine and lersivirine on days 1–14. In study 2, individuals received lersivirine and tenofovir DF/emtricitabine, lersivirine and placebo or tenofovir DF/emtricitabine and placebo on days 1–10. In study 3, individuals received abacavir/ lamivudine only in period 1 (5 days) and abacavir/lamivudine and lersivirine in period 2 (10 days). Blood samples were taken on days 1–14 (study 1) or day of final dose (studies 2 and 3) and analysed using high performance liquid chromatography/dual mass spectrometry. Pharmacokinetic parameters were calculated by standard non-compartmental methods.
Results
When coadministered with lersivirine, zidovudine exposure increased by 35%, and exposure of its metabolite zidovudine-glucuronide decreased by 19%. Following coadministration of lersivirine and tenofovir DF/emtricitabine, tenofovir exposure increased by 30%, and lersivirine exposure decreased by 12%. Coadministration of lersivirine and abacavir/lamivudine increased abacavir exposure by 27% and decreased lamivudine exposure by 8%. Adverse events were predominantly mild in these Phase I studies.
Conclusions
Coadministration of lersivirine with zidovudine, tenofovir DF/emtricitabine or abacavir/lamivudine influenced the systemic exposure of all nucleoside reverse transcriptase inhibitor agents investigated (except for lamivudine; emtricitabine pharmacokinetics were not assessed). Changes were not considered clinically meaningful for zidovudine and abacavir. The clinical relevance of the effect on tenofovir pharmacokinetics is currently unknown.
References
1.
DaarE.S., RichmanD.D.Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses2005; 21: 343–357.
2.
HammerS.M., EronJ.J.Jr., ReissP.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA2008; 300: 555–570.
3.
MoriJ., CorbauR., LewisD.In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor.15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract F-134.
4.
FätkenheuerG., StaszewskiS., PlettenburgA.Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS2009; 23: 2115–2122.
5.
VourvahisM., GleaveM., NeddermanA.N.Excretion and metabolism of lersivirine (UK-453,061), a next generation NNRTI, following administration of [14C] lersivirine to healthy volunteers. Drug Metab Dispos2010; 38: 789–800.
6.
VealG.J., BackD.J.Metabolism of zidovudine. Gen Pharmacol1995; 26: 1469–1475.
7.
Truvada (tenofovir disoproxil fumarate/emtricitabine).Prescribing information 2009.Gilead SciencesFoster City, CA, USA.
8.
ImaokaT., KusuharaH., AdachiM., SchuetzJ.D., TakeuchiK., SugiyamaY.Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol2007; 71: 619–627.
9.
UwaiY., IdaH., TsujiY., KatsuraT., InuiK.Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res2007; 24: 811–815.
10.
van GelderJ., DefermeS., NaesensL.Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos2002; 30: 924–930.
11.
Epzicom/Kivexa (abacavir sulphate/lamivudine).Prescribing information 2011. ViiV HealthcareBrentford, UK.
12.
Ziagen (abacavir sulphate).Prescribing information 2010. ViiV HealthcareBrentford, UK.
13.
SleasmanJ.W., RobbinsB.L., CrossS.J.Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. Clin Pharmacol Ther2009; 85: 394–401.
14.
LangdonG., DavisJ., LaytonG., ChongC.L., WeissgerberG., VourvahisM.Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine(UK-453,061), in healthy adult subjects. Br J Clin Pharmacol2012; 73: 768–775.
15.
UchaipichatV., WinnerL.K., MackenzieP.I., ElliotD.J., WilliamsJ.A., MinersJ.O.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol2006; 61: 427–439.
16.
LertoraJ.J., RegeA.B., GreenspanD.L.Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther1994; 56: 272–278.
17.
Retrovir (zidovudine).Prescribing information 2011. ViiV HealthcareBrentford, UK.
18.
PerloffE.S., DuanS.X., SkolnikP.R., GreenblattD.J., von MoltkeL.L.Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos2005; 33: 764–770.
19.
Viread (tenofovir disoproxil fumarate).Prescribing information 2010. Gilead SciencesFoster City, CA, USA.
20.
ClumeckN., van LunzenJ., ChiliadeP.ARTEMIS: efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients.11th European AIDS Conference. 24–27 October 2007, Madrid, Spain. Abstract LBPS7/5.
21.
DeJesusE., OrtizR., KhanlouH.Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211).47th Interscience Conference on Antimicrobial Agents and Chemotherapy.17–20 September 2007, Chicago, IL, USA. Abstract H-718b.
22.
MolinaJ-M, Andrade-VillanuevaJ., EchevarriaJ.Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1-infected subjects: The CASTLE study, 48-week results.15th Conference on Retroviruses and Opportunistic Infections, 3–6 February 2008, Boston, MA, USA. Abstract 37.
23.
YoungJ., SchaferJ., FuxC.A.Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS2012; 26: 567–575.
24.
VernazzaP., WangC., PozniakA.Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing multicentre, randomised, double-blind, Phase IIIb trial (Study A5271015).16th International AIDS Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Abstract TUAB0101.
25.
Nakatani-FreshwaterT., TaftD.R.Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci2008; 97: 5401–5410.
26.
MooreK.H., YuenG.J., RaaschR.H.Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther1996; 59: 550–558.
27.
VourvahisM., GleaveM., NeddermanA., GardnerI., LabadieR.Mass balance of lersivirine (UK-453,061), a next-generation NNRTI, following administration of [14C] lersivirine to healthy volunteers.10th International Workshop on the Clinical Pharmacology of HIV Therapy. 15–17 April 2009, Amsterdam, the Netherlands. Poster P61.
